it's heartening to see news coming.
Commencing vap trial and presenting at conferences is all positive.
We really need to see the press release announcing the rest of world deal for LANI. Based on the anaconda deal numbers it should be worth much more than I have previously proposed. And I hope the anaconda deal was done with the understanding that the LANI deal would soon increase cash reserves.
So with RSV compound at Phase 1, Vapendavir in Phase 2 b, Anaconda's drug coming to Phase 2b, and LANI potentially at Phase 3: well, that's reasonable biotech-bait.
No comments:
Post a Comment